During cancer development, p53 is either stripped of its power through DNA mutation, as occurs in around 50% of human cancers; or by functional disruption, as implicated in the remainder (Olivier et al., 2010; Donehower et al., 2019). The gene discussed is TP53; the disease is cancer.